Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy
Defective inflammation resolution is the underlying cause of prevalent chronic inflammatory diseases, such as arthritis, asthma, cancer, and neurodegenerative and cardiovascular diseases. Inflammation resolution is governed by several endogenous factors, including fatty acid-derived specialized pror...
Gespeichert in:
| Veröffentlicht in: | The American journal of pathology Jg. 187; H. 6; S. 1211 |
|---|---|
| Hauptverfasser: | , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.06.2017
|
| Schlagworte: | |
| ISSN: | 1525-2191, 1525-2191 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Defective inflammation resolution is the underlying cause of prevalent chronic inflammatory diseases, such as arthritis, asthma, cancer, and neurodegenerative and cardiovascular diseases. Inflammation resolution is governed by several endogenous factors, including fatty acid-derived specialized proresolving mediators and proteins, such as annexin A1. Specifically, specialized proresolving mediators comprise a family of mediators that include arachidonic acid-derived lipoxins, omega-3 fatty acid eicosapentaenoic acid-derived resolvins, docosahexaenoic acid-derived resolvins, protectins, and maresins. Emerging evidence indicates that imbalances between specialized proresolving mediators and proinflammatory mediators are associated with several prevalent human diseases, including atherosclerosis. Mechanisms that drive this imbalance remain largely unknown and will be discussed in this review. Furthermore, the concept of dysregulated inflammation resolution in atherosclerosis has been known for several decades. Recently, there has been an explosion of new work with regard to the therapeutic application of proresolving ligands in experimental atherosclerosis. Therefore, this review will highlight recent advances in our understanding of how inflammation resolution may become defective in atherosclerosis and the potential for proresolving therapeutics in atherosclerosis. Last, we offer insight for future implications of the field. |
|---|---|
| AbstractList | Defective inflammation resolution is the underlying cause of prevalent chronic inflammatory diseases, such as arthritis, asthma, cancer, and neurodegenerative and cardiovascular diseases. Inflammation resolution is governed by several endogenous factors, including fatty acid-derived specialized proresolving mediators and proteins, such as annexin A1. Specifically, specialized proresolving mediators comprise a family of mediators that include arachidonic acid-derived lipoxins, omega-3 fatty acid eicosapentaenoic acid-derived resolvins, docosahexaenoic acid-derived resolvins, protectins, and maresins. Emerging evidence indicates that imbalances between specialized proresolving mediators and proinflammatory mediators are associated with several prevalent human diseases, including atherosclerosis. Mechanisms that drive this imbalance remain largely unknown and will be discussed in this review. Furthermore, the concept of dysregulated inflammation resolution in atherosclerosis has been known for several decades. Recently, there has been an explosion of new work with regard to the therapeutic application of proresolving ligands in experimental atherosclerosis. Therefore, this review will highlight recent advances in our understanding of how inflammation resolution may become defective in atherosclerosis and the potential for proresolving therapeutics in atherosclerosis. Last, we offer insight for future implications of the field.Defective inflammation resolution is the underlying cause of prevalent chronic inflammatory diseases, such as arthritis, asthma, cancer, and neurodegenerative and cardiovascular diseases. Inflammation resolution is governed by several endogenous factors, including fatty acid-derived specialized proresolving mediators and proteins, such as annexin A1. Specifically, specialized proresolving mediators comprise a family of mediators that include arachidonic acid-derived lipoxins, omega-3 fatty acid eicosapentaenoic acid-derived resolvins, docosahexaenoic acid-derived resolvins, protectins, and maresins. Emerging evidence indicates that imbalances between specialized proresolving mediators and proinflammatory mediators are associated with several prevalent human diseases, including atherosclerosis. Mechanisms that drive this imbalance remain largely unknown and will be discussed in this review. Furthermore, the concept of dysregulated inflammation resolution in atherosclerosis has been known for several decades. Recently, there has been an explosion of new work with regard to the therapeutic application of proresolving ligands in experimental atherosclerosis. Therefore, this review will highlight recent advances in our understanding of how inflammation resolution may become defective in atherosclerosis and the potential for proresolving therapeutics in atherosclerosis. Last, we offer insight for future implications of the field. Defective inflammation resolution is the underlying cause of prevalent chronic inflammatory diseases, such as arthritis, asthma, cancer, and neurodegenerative and cardiovascular diseases. Inflammation resolution is governed by several endogenous factors, including fatty acid-derived specialized proresolving mediators and proteins, such as annexin A1. Specifically, specialized proresolving mediators comprise a family of mediators that include arachidonic acid-derived lipoxins, omega-3 fatty acid eicosapentaenoic acid-derived resolvins, docosahexaenoic acid-derived resolvins, protectins, and maresins. Emerging evidence indicates that imbalances between specialized proresolving mediators and proinflammatory mediators are associated with several prevalent human diseases, including atherosclerosis. Mechanisms that drive this imbalance remain largely unknown and will be discussed in this review. Furthermore, the concept of dysregulated inflammation resolution in atherosclerosis has been known for several decades. Recently, there has been an explosion of new work with regard to the therapeutic application of proresolving ligands in experimental atherosclerosis. Therefore, this review will highlight recent advances in our understanding of how inflammation resolution may become defective in atherosclerosis and the potential for proresolving therapeutics in atherosclerosis. Last, we offer insight for future implications of the field. |
| Author | Fredman, Gabrielle Tabas, Ira |
| Author_xml | – sequence: 1 givenname: Gabrielle surname: Fredman fullname: Fredman, Gabrielle email: fredmag@mail.amc.edu organization: Department of Molecular and Cellular Physiology, Center for Cardiovascular Sciences, Albany Medical College, Albany, New York. Electronic address: fredmag@mail.amc.edu – sequence: 2 givenname: Ira surname: Tabas fullname: Tabas, Ira organization: Departments of Medicine, Pathology and Cell Biology, and Physiology, Columbia University Medical Center, New York, New York |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28527709$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkF9LwzAUxYNMnJt-A5E--tKaZPnT-jaH08FQGPO53Lapy2iTmqTgvr2rThAu9_4493AezgSNjDUKoRuCE4KJuN8nsO8g7BKKiUwwOU56hi4JpzymJCOjfzxGE-_3GGMxS_EFGtOUUylxdok2j9b6oM1HtDJ1A20LQVsTbZS3Tf-D2kTzsFPO-rIZtvYP0Xanolf1FaKlsyZo5aLaukF10B2u0HkNjVfXpztF78un7eIlXr89rxbzddxRIUIMrCh4yWhRpEJCxRnJSlbIimQgKKuYnAEXuOZQpRRYLeXxr3jN6hLjigKnU3T3m9s5-9krH_JW-1I1DRhle5-TDJPZUNVgvT1Z-6JVVd453YI75H890G86dmPC |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ajpath.2017.01.018 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1525-2191 |
| ExternalDocumentID | 28527709 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL127464 – fundername: NHLBI NIH HHS grantid: R01 HL132412 |
| GroupedDBID | --- --K -~X .1- .55 .FO .GJ 0R~ 1P~ 23M 2WC 34R 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 7X7 88E 88I 8AF 8C1 8FE 8FH 8FI 8FJ 8R4 8R5 AAEDT AAEDW AAFWJ AAIKJ AALRI AAQFI AAQXK AAXUO AAYWO ABCQX ABJNI ABLJU ABMAC ABOCM ABUWG ABWVN ACGFO ACGOD ACPRK ACRPL ACVFH ADBBV ADCNI ADEZE ADHJS ADMUD ADNMO ADVLN AENEX AEUPX AEVXI AFCTW AFFNX AFJKZ AFKRA AFPUW AFRHN AFTJW AGCQF AGHFR AGQPQ AHDRD AHMBA AI. AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALIPV ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BELOY BENPR BHPHI BPHCQ BVXVI C1A CCPQU CGR CS3 CUY CVF DIK DWQXO E3Z EBS ECM EFJIC EFKBS EIF EJD F5P FDB FEDTE FGOYB FYUFA GBLVA GNUQQ GX1 H13 HCIFZ HMCUK HVGLF HX~ HZ~ IH2 IXB J5H KOM KQ8 L7B LID LK8 M1P M2P M41 M7P MVM N9A NPM O9- OG~ OHT OK1 OS. P2P PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X R2- ROL RPM SEL SES SJN SSZ TIP TR2 UKHRP VH1 WH7 WOQ X7M XH2 Y6R YHG YNH Z5R ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-p266t-a4bb5c42bb867ad5419c4b7d19a624d473a560f5ad82a4f7719ce5f4fc00d2a52 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 145 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000402221500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1525-2191 |
| IngestDate | Sun Nov 09 13:24:23 EST 2025 Mon Jul 21 05:51:55 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p266t-a4bb5c42bb867ad5419c4b7d19a624d473a560f5ad82a4f7719ce5f4fc00d2a52 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 28527709 |
| PQID | 1901310165 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1901310165 pubmed_primary_28527709 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-Jun 20170601 |
| PublicationDateYYYYMMDD | 2017-06-01 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-Jun |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The American journal of pathology |
| PublicationTitleAlternate | Am J Pathol |
| PublicationYear | 2017 |
| References | 15238606 - J Exp Med. 2004 Jul 5;200(1):69-78 22183178 - J Thromb Thrombolysis. 2012 Feb;33(2):143-53 25520364 - Circ Res. 2015 Feb 27;116(5):827-35 19265038 - Circ Res. 2009 Mar 27;104(6):e42-54 12588790 - J Appl Physiol (1985). 2003 Jun;94(6):2237-40 16908763 - Circulation. 2006 Aug 29;114(9):929-35 25904598 - Circ Res. 2015 Jun 19;117(1):e1-e11 16293697 - Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17501-6 24952646 - Nat Med. 2014 Jul;20(7):754-8 12391014 - J Exp Med. 2002 Oct 21;196(8):1025-37 27531933 - Circ Res. 2016 Oct 14;119(9):1030-1038 27121596 - FASEB J. 2016 Aug;30(8):2792-801 24325951 - Arthritis Res Ther. 2013;15(6):R212 16282974 - Nat Genet. 2006 Jan;38(1):68-74 17568749 - Nature. 2007 Jun 14;447(7146):869-74 20303877 - Cell. 2010 Mar 19;140(6):871-82 26090792 - PLoS One. 2015 Jun 19;10(6):e0130484 11034610 - J Exp Med. 2000 Oct 16;192(8):1197-204 25695999 - Sci Transl Med. 2015 Feb 18;7(275):275ra20 27199481 - Proc Natl Acad Sci U S A. 2016 Jun 7;113(23 ):6526-31 25881761 - Joint Bone Spine. 2015 Jul;82(4):258-63 26289316 - FASEB J. 2015 Dec;29(12 ):5029-43 25791806 - Nanomedicine. 2015 Jul;11(5):1039-46 21935407 - PLoS One. 2011;6(9):e24422 10657608 - J Immunol. 2000 Feb 15;164(4):1663-7 15034576 - Nat Immunol. 2004 Apr;5(4):388-92 17384141 - FASEB J. 2007 Jul;21(9):2257-66 14770184 - Nat Genet. 2004 Mar;36(3):233-9 23484005 - PLoS One. 2013;8(3):e58258 16698924 - Proc Natl Acad Sci U S A. 2006 May 23;103(21):8161-6 26660549 - Physiol Rep. 2015 Dec;3(12):null 21711247 - Biochem J. 2011 Jul 15;437(2):185-97 9351616 - Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1157-64 11884288 - Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):443-9 20435846 - Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H153-64 27632672 - Crit Care Med. 2017 Jan;45(1):58-68 26195725 - J Exp Med. 2015 Jul 27;212(8):1203-17 25870158 - J Mol Cell Cardiol. 2015 Jul;84:24-35 15886380 - JAMA. 2005 May 11;293(18):2245-56 27236706 - Atherosclerosis. 2016 Jul;250:158-65 22904297 - Blood. 2012 Oct 11;120(15):e60-72 6354352 - Br Med Bull. 1983 Jul;39(3):271-6 25792445 - Arterioscler Thromb Vasc Biol. 2015 May;35(5):1123-33 15961693 - Am J Respir Crit Care Med. 2005 Oct 1;172(7):824-30 25512512 - Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18685-90 23307734 - Science. 2013 Jan 11;339(6116):166-72 18559988 - FASEB J. 2008 Oct;22(10):3595-606 14702425 - N Engl J Med. 2004 Jan 1;350(1):29-37 23333278 - Cell Rep. 2013 Jan 31;3(1):200-10 25217660 - Am J Physiol Lung Cell Mol Physiol. 2014 Nov 15;307(10):L746-57 27052783 - J Atheroscler Thromb. 2016 Jun 1;23 (6):655-64 27437576 - Nature. 2016 Aug 4;536(7614):86-90 27158677 - JCI Insight. 2016 Apr 21;1(5):e85922 26095908 - Semin Immunol. 2015 May;27(3):227-33 27534559 - J Immunol. 2016 Sep 15;197(6):2362-8 26517695 - J Clin Invest. 2015 Oct 26;125(12):4334-48 27340271 - Circ Res. 2016 Jun 24;119(1):113-30 23554707 - J Biomed Res. 2011 Sep;25(5):319-27 26052006 - Cell Metab. 2015 Jul 7;22(1):125-37 20702811 - Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):2005-13 26588184 - J Cell Physiol. 2016 Jul;231(7):1621-7 6894485 - Nature. 1981 May 28;291(5813):323-4 8751717 - FASEB J. 1996 Aug;10(10):1147-58 20709806 - Am J Pathol. 2010 Oct;177(4):2116-23 10371510 - Nat Med. 1999 Jun;5(6):698-701 21828049 - J Biol Chem. 2011 Sep 23;286(38):33335-44 27100066 - ACS Nano. 2016 May 24;10(5):5280-92 26236990 - Nat Med. 2015 Sep;21(9):1071-5 26892968 - Circ Res. 2016 Feb 19;118(4):703-20 15322539 - Nat Med. 2004 Sep;10(9):966-73 27547824 - JCI Insight. 2016 Aug 4;1(12):null 24902971 - Circ Res. 2014 Jun 6;114(12):1867-79 27532042 - Sci Adv. 2016 Jul 22;2(7):e1600224 18451332 - Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1421-8 25246560 - Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14530-5 27015770 - Nanomedicine. 2016 Aug;12(6):1463-70 15935589 - Exp Gerontol. 2005 Jul;40(7):612-4 17267386 - FASEB J. 2007 Feb;21(2):325-32 22686415 - N Engl J Med. 2012 Jul 26;367(4):309-18 11781349 - J Clin Invest. 2002 Jan;109(1):41-50 14592543 - Thromb Res. 2003 Jun 15;110(5-6):255-8 16127181 - Circ J. 2005 Sep;69(9):1029-34 22957142 - Sci Rep. 2012;2:639 22997156 - Cardiovasc Res. 2013 Jan 1;97(1):125-33 24175059 - JRSM Cardiovasc Dis. 2012 Apr 05;1(1):null 27559094 - Sci Transl Med. 2016 Aug 24;8(353):353ra111 20107188 - J Immunol. 2010 Mar 1;184(5):2611-9 24696140 - Am J Physiol Cell Physiol. 2014 Jul 1;307(1):C39-54 23407709 - FASEB J. 2013 Jun;27(6):2220-32 27135421 - Aging Cell. 2016 Aug;15(4):766-77 22622040 - J Clin Invest. 2012 Jun;122(6):1973-90 20080636 - Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5 18480426 - Blood. 2008 Aug 1;112(3):848-55 10339595 - Proc Natl Acad Sci U S A. 1999 May 25;96(11):6377-81 18467644 - Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1429-31 28067670 - J Clin Invest. 2017 Feb 1;127(2):564-568 25139986 - Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12746-51 1617790 - Circulation. 1992 Jul;86(1):56-63 20421472 - Proc Natl Acad Sci U S A. 2010 May 11;107(19):8842-7 12368905 - Nat Med. 2002 Nov;8(11):1296-302 24899309 - Nature. 2014 Jun 5;510(7503):92-101 27034112 - J Vasc Surg. 2017 Jan;65(1):207-217.e3 27461565 - FASEB J. 2016 Nov;30(11):3714-3725 27025886 - J Am Heart Assoc. 2016 Mar 29;5(3):e002814 27207555 - Diabetes. 2016 Aug;65(8):2139-50 11429545 - Nat Immunol. 2001 Jul;2(7):612-9 25550206 - Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):525-34 27313451 - Int J Chron Obstruct Pulmon Dis. 2016 May 27;11:1119-28 21628447 - FASEB J. 2011 Sep;25(9):2967-79 11687254 - J Immunol Methods. 2001 Nov 1;257(1-2):213-20 27508346 - J Biomed Mater Res A. 2017 Jan;105(1):31-41 11891303 - Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3902-7 16606835 - Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6326-31 17982093 - J Immunol. 2007 Nov 15;179(10):7021-9 27893465 - J Clin Invest. 2017 Jan 3;127(1):169-182 8245774 - J Exp Med. 1993 Dec 1;178(6):1935-46 21478260 - FASEB J. 2011 Jul;25(7):2399-407 27659679 - Nat Commun. 2016 Sep 23;7:12859 19960040 - Nat Rev Immunol. 2010 Jan;10(1):36-46 22538616 - Nature. 2012 Apr 25;484(7395):524-8 25217168 - J Immunol. 2014 Oct 15;193(8):4235-44 |
| References_xml | – reference: 25791806 - Nanomedicine. 2015 Jul;11(5):1039-46 – reference: 12588790 - J Appl Physiol (1985). 2003 Jun;94(6):2237-40 – reference: 27632672 - Crit Care Med. 2017 Jan;45(1):58-68 – reference: 20080636 - Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5 – reference: 22957142 - Sci Rep. 2012;2:639 – reference: 20435846 - Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H153-64 – reference: 25217660 - Am J Physiol Lung Cell Mol Physiol. 2014 Nov 15;307(10):L746-57 – reference: 26095908 - Semin Immunol. 2015 May;27(3):227-33 – reference: 19960040 - Nat Rev Immunol. 2010 Jan;10(1):36-46 – reference: 15961693 - Am J Respir Crit Care Med. 2005 Oct 1;172(7):824-30 – reference: 24952646 - Nat Med. 2014 Jul;20(7):754-8 – reference: 11884288 - Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):443-9 – reference: 22183178 - J Thromb Thrombolysis. 2012 Feb;33(2):143-53 – reference: 26195725 - J Exp Med. 2015 Jul 27;212(8):1203-17 – reference: 27236706 - Atherosclerosis. 2016 Jul;250:158-65 – reference: 15886380 - JAMA. 2005 May 11;293(18):2245-56 – reference: 18451332 - Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1421-8 – reference: 22686415 - N Engl J Med. 2012 Jul 26;367(4):309-18 – reference: 6894485 - Nature. 1981 May 28;291(5813):323-4 – reference: 26588184 - J Cell Physiol. 2016 Jul;231(7):1621-7 – reference: 12391014 - J Exp Med. 2002 Oct 21;196(8):1025-37 – reference: 27199481 - Proc Natl Acad Sci U S A. 2016 Jun 7;113(23 ):6526-31 – reference: 27893465 - J Clin Invest. 2017 Jan 3;127(1):169-182 – reference: 27437576 - Nature. 2016 Aug 4;536(7614):86-90 – reference: 19265038 - Circ Res. 2009 Mar 27;104(6):e42-54 – reference: 20709806 - Am J Pathol. 2010 Oct;177(4):2116-23 – reference: 17568749 - Nature. 2007 Jun 14;447(7146):869-74 – reference: 23307734 - Science. 2013 Jan 11;339(6116):166-72 – reference: 11891303 - Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3902-7 – reference: 17384141 - FASEB J. 2007 Jul;21(9):2257-66 – reference: 14770184 - Nat Genet. 2004 Mar;36(3):233-9 – reference: 15935589 - Exp Gerontol. 2005 Jul;40(7):612-4 – reference: 6354352 - Br Med Bull. 1983 Jul;39(3):271-6 – reference: 27508346 - J Biomed Mater Res A. 2017 Jan;105(1):31-41 – reference: 18559988 - FASEB J. 2008 Oct;22(10):3595-606 – reference: 26236990 - Nat Med. 2015 Sep;21(9):1071-5 – reference: 17267386 - FASEB J. 2007 Feb;21(2):325-32 – reference: 22538616 - Nature. 2012 Apr 25;484(7395):524-8 – reference: 20107188 - J Immunol. 2010 Mar 1;184(5):2611-9 – reference: 9351616 - Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1157-64 – reference: 12368905 - Nat Med. 2002 Nov;8(11):1296-302 – reference: 28067670 - J Clin Invest. 2017 Feb 1;127(2):564-568 – reference: 26052006 - Cell Metab. 2015 Jul 7;22(1):125-37 – reference: 8245774 - J Exp Med. 1993 Dec 1;178(6):1935-46 – reference: 21628447 - FASEB J. 2011 Sep;25(9):2967-79 – reference: 25139986 - Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12746-51 – reference: 25520364 - Circ Res. 2015 Feb 27;116(5):827-35 – reference: 21828049 - J Biol Chem. 2011 Sep 23;286(38):33335-44 – reference: 27532042 - Sci Adv. 2016 Jul 22;2(7):e1600224 – reference: 27534559 - J Immunol. 2016 Sep 15;197(6):2362-8 – reference: 21478260 - FASEB J. 2011 Jul;25(7):2399-407 – reference: 16127181 - Circ J. 2005 Sep;69(9):1029-34 – reference: 15034576 - Nat Immunol. 2004 Apr;5(4):388-92 – reference: 27207555 - Diabetes. 2016 Aug;65(8):2139-50 – reference: 24175059 - JRSM Cardiovasc Dis. 2012 Apr 05;1(1):null – reference: 18480426 - Blood. 2008 Aug 1;112(3):848-55 – reference: 27559094 - Sci Transl Med. 2016 Aug 24;8(353):353ra111 – reference: 27034112 - J Vasc Surg. 2017 Jan;65(1):207-217.e3 – reference: 22997156 - Cardiovasc Res. 2013 Jan 1;97(1):125-33 – reference: 24902971 - Circ Res. 2014 Jun 6;114(12):1867-79 – reference: 24899309 - Nature. 2014 Jun 5;510(7503):92-101 – reference: 26660549 - Physiol Rep. 2015 Dec;3(12):null – reference: 11429545 - Nat Immunol. 2001 Jul;2(7):612-9 – reference: 27340271 - Circ Res. 2016 Jun 24;119(1):113-30 – reference: 23554707 - J Biomed Res. 2011 Sep;25(5):319-27 – reference: 24325951 - Arthritis Res Ther. 2013;15(6):R212 – reference: 26090792 - PLoS One. 2015 Jun 19;10(6):e0130484 – reference: 24696140 - Am J Physiol Cell Physiol. 2014 Jul 1;307(1):C39-54 – reference: 11781349 - J Clin Invest. 2002 Jan;109(1):41-50 – reference: 26892968 - Circ Res. 2016 Feb 19;118(4):703-20 – reference: 25904598 - Circ Res. 2015 Jun 19;117(1):e1-e11 – reference: 23484005 - PLoS One. 2013;8(3):e58258 – reference: 16293697 - Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17501-6 – reference: 27100066 - ACS Nano. 2016 May 24;10(5):5280-92 – reference: 21935407 - PLoS One. 2011;6(9):e24422 – reference: 25695999 - Sci Transl Med. 2015 Feb 18;7(275):275ra20 – reference: 27547824 - JCI Insight. 2016 Aug 4;1(12):null – reference: 25792445 - Arterioscler Thromb Vasc Biol. 2015 May;35(5):1123-33 – reference: 10371510 - Nat Med. 1999 Jun;5(6):698-701 – reference: 20421472 - Proc Natl Acad Sci U S A. 2010 May 11;107(19):8842-7 – reference: 16606835 - Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6326-31 – reference: 11687254 - J Immunol Methods. 2001 Nov 1;257(1-2):213-20 – reference: 27052783 - J Atheroscler Thromb. 2016 Jun 1;23 (6):655-64 – reference: 1617790 - Circulation. 1992 Jul;86(1):56-63 – reference: 27461565 - FASEB J. 2016 Nov;30(11):3714-3725 – reference: 23333278 - Cell Rep. 2013 Jan 31;3(1):200-10 – reference: 27025886 - J Am Heart Assoc. 2016 Mar 29;5(3):e002814 – reference: 25246560 - Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14530-5 – reference: 15238606 - J Exp Med. 2004 Jul 5;200(1):69-78 – reference: 26289316 - FASEB J. 2015 Dec;29(12 ):5029-43 – reference: 16908763 - Circulation. 2006 Aug 29;114(9):929-35 – reference: 10339595 - Proc Natl Acad Sci U S A. 1999 May 25;96(11):6377-81 – reference: 27313451 - Int J Chron Obstruct Pulmon Dis. 2016 May 27;11:1119-28 – reference: 23407709 - FASEB J. 2013 Jun;27(6):2220-32 – reference: 26517695 - J Clin Invest. 2015 Oct 26;125(12):4334-48 – reference: 22904297 - Blood. 2012 Oct 11;120(15):e60-72 – reference: 27659679 - Nat Commun. 2016 Sep 23;7:12859 – reference: 25870158 - J Mol Cell Cardiol. 2015 Jul;84:24-35 – reference: 18467644 - Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1429-31 – reference: 20303877 - Cell. 2010 Mar 19;140(6):871-82 – reference: 17982093 - J Immunol. 2007 Nov 15;179(10):7021-9 – reference: 10657608 - J Immunol. 2000 Feb 15;164(4):1663-7 – reference: 27158677 - JCI Insight. 2016 Apr 21;1(5):e85922 – reference: 21711247 - Biochem J. 2011 Jul 15;437(2):185-97 – reference: 25881761 - Joint Bone Spine. 2015 Jul;82(4):258-63 – reference: 27135421 - Aging Cell. 2016 Aug;15(4):766-77 – reference: 27015770 - Nanomedicine. 2016 Aug;12(6):1463-70 – reference: 25512512 - Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18685-90 – reference: 20702811 - Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):2005-13 – reference: 25550206 - Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):525-34 – reference: 8751717 - FASEB J. 1996 Aug;10(10):1147-58 – reference: 15322539 - Nat Med. 2004 Sep;10(9):966-73 – reference: 16282974 - Nat Genet. 2006 Jan;38(1):68-74 – reference: 14702425 - N Engl J Med. 2004 Jan 1;350(1):29-37 – reference: 14592543 - Thromb Res. 2003 Jun 15;110(5-6):255-8 – reference: 16698924 - Proc Natl Acad Sci U S A. 2006 May 23;103(21):8161-6 – reference: 27531933 - Circ Res. 2016 Oct 14;119(9):1030-1038 – reference: 27121596 - FASEB J. 2016 Aug;30(8):2792-801 – reference: 11034610 - J Exp Med. 2000 Oct 16;192(8):1197-204 – reference: 22622040 - J Clin Invest. 2012 Jun;122(6):1973-90 – reference: 25217168 - J Immunol. 2014 Oct 15;193(8):4235-44 |
| SSID | ssj0006380 |
| Score | 2.587034 |
| SecondaryResourceType | review_article |
| Snippet | Defective inflammation resolution is the underlying cause of prevalent chronic inflammatory diseases, such as arthritis, asthma, cancer, and neurodegenerative... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1211 |
| SubjectTerms | Animals Anti-Inflammatory Agents - therapeutic use Atherosclerosis - drug therapy Atherosclerosis - etiology Atherosclerosis - metabolism Atherosclerosis - pathology Collagen - biosynthesis Disease Progression Humans Immunologic Factors - therapeutic use Inflammation - complications Inflammation - drug therapy Inflammation - metabolism Inflammation Mediators - metabolism Molecular Targeted Therapy - methods Plaque, Atherosclerotic - drug therapy Plaque, Atherosclerotic - etiology Plaque, Atherosclerotic - metabolism Plaque, Atherosclerotic - pathology Regeneration - physiology Wound Healing - physiology |
| Title | Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28527709 https://www.proquest.com/docview/1901310165 |
| Volume | 187 |
| WOSCitedRecordID | wos000402221500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPBa3KZJk3gRFRc9bFlEYW8lTVJYD-1qV3-_M2mXPQmClxxaGkryzczHPAm5kjaxjmF8kAN946yVuTQymgvhnWVxwcOwCZllajLR487h1nRplQudGBS1qy36yK_RcCWh-OZ29hHh1CiMrnYjNFZJLwEqg6iWk2W3cMBWKIgUTEQgmfGidC7kd5l3nPmLyV0yNO6M1e8kMxib4fZ_f3OHbHU0k961uNglK77aIxujLpC-T17u67rBjGf6XJUAiraAkaIzv4UinVb0Dslh3cAGsE6bGwqYohloczrEtgdgUClQXnyKjQkOyNvw8fXhKerGK0QzsMrzyPCiEJazolCpNE7wWFteSBdrkzLuuEwM0KFSGKeY4aWU8N6Lkpd2MHDMCHZI1qq68seEaqWFVoYPnEq4hR1LY4wueaqc91awPrlcnFYO8MWYhKl8_dXky_Pqk6P2yPNZ22cjZ0owKQf65A9fn5JNvMk2ieuM9EoQXn9O1u33fNp8XgRcwJqNRz9basJf |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Boosting+Inflammation+Resolution+in+Atherosclerosis%3A+The+Next+Frontier+for+Therapy&rft.jtitle=The+American+journal+of+pathology&rft.au=Fredman%2C+Gabrielle&rft.au=Tabas%2C+Ira&rft.date=2017-06-01&rft.eissn=1525-2191&rft.volume=187&rft.issue=6&rft.spage=1211&rft_id=info:doi/10.1016%2Fj.ajpath.2017.01.018&rft_id=info%3Apmid%2F28527709&rft_id=info%3Apmid%2F28527709&rft.externalDocID=28527709 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1525-2191&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1525-2191&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1525-2191&client=summon |